Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 3/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935646 | 1.00 | TDO2 (0.64) | TDO2CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL7844961 | 0.86 | CYP2A6 (0.57) | TDO2CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL29935857 | 0.85 | CAPN1 (0.59) | TDO2CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL208051 | 0.85 | CAPN1 (0.59) | TDO2CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL15331451 | 0.82 | CYP2A6 (0.53) | TDO2CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL9377060 | 0.79 | CYP2A6 (0.66) | TDO2CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL29956305 | 0.79 | CYP2A6 (0.66) | TDO2CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL19178919 | 0.78 | TDO2 (1.00) | TDO2KDM4EALDH1A1MAPTGPR84 | |
| SCHEMBL639590 | 0.78 | CYP2A6 (0.64) | TDO2CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL1049957 | 0.78 | PIM3 (0.65) | TDO2CYP2A6KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-116670127-A | EGFR inhibitors and compositions and uses thereof | 贝达药业股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-103755980-B | A kind of preparation method of autofluorescence nano-micelle | XIAMEN UNIVERSITY (CN) | 2015-12-09 | — | — | CN | claimed |
| CN-103755980-A | Preparation method of spontaneous fluorescence nano micelle | UNIV XIAMEN | 2014-04-30 | — | — | CN | claimed |
| CN-116535386-B | Cyanoethylene sulfonyl anilide compound and preparation method and medical application thereof | 西南大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-116082412-B | Metal complex of tail-connected TDO inhibitor and preparation method and application thereof | 南京师范大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | GENETOLEAD INC. (CA) | 2024-12-12 | — | — | US | disclosed |
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240246965-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | EQUINORM LTD | 2024-07-25 | — | — | US | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2004019943-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-0812825-B1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2004-02-11 | — | — | EP | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | disclosed |
| US-5952355-A | 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| CN-1172476-A | Propenone derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0812825-A1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | TDO2 588/4885CYP2A6 575/4885KDM4E 4534/4885 |
| US-20240246965-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | CNR1, CNR2, OPRK1 | TDO2 3835/4885CYP2A6 82/4885KDM4E 1392/4885 |
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | TDO2 4604/4885CYP2A6 3388/4885KDM4E 4019/4885 |
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | TDO2 2950/4885CYP2A6 931/4885KDM4E 1051/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | TDO2 3977/4885CYP2A6 3717/4885KDM4E 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.